Omalizumab
Treatment for Asthma
Typical Dosage: 75-375 mg every 2 or 4 weeks
Effectiveness
80%
Safety Score
60%
Clinical Trials
112
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
75-375 mg every 2 or 4 weeks
Time to Effect
3-6 months
Treatment Duration
long-term
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
750(Treat 750 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$25,000
Monitoring:$1,000
Side Effect Mgmt:$200
Total Annual:$26,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$150,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$40,308
Cost per Remission
$174,667
Comparison vs High-dose ICS/LABA + LTRA
Cost Difference
+$24,200/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Active Clinical Trials
1 active trial recruiting for Omalizumab in Asthma
Biologics and Sublingual Immunotherapy
NCT06027073NOT YET RECRUITINGPHASE4
150 participants
INTERVENTIONAL
Started: May 1, 2024
Completed Clinical Trials
13 completed trials for Omalizumab in Asthma
Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma
NCT00546143COMPLETEDPHASE4
32 participants
INTERVENTIONAL
Berlin, Germany +4 more
Started: Jul 1, 2007
XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States
NCT05157087COMPLETED
16.2K participants
OBSERVATIONAL
East Hanover, United States
Started: Mar 1, 2020
Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
NCT00829179COMPLETEDPHASE3
20 participants
INTERVENTIONAL
Durham, United States
Started: Oct 1, 2002
Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy
NCT00329381COMPLETEDPHASE4
14 participants
INTERVENTIONAL
Jackson, United States
Started: May 1, 2006
The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety
NCT04778137COMPLETEDPHASE1
114 participants
INTERVENTIONAL
Shanghai, China
Started: Dec 1, 2020
Inner-City Anti-IgE Therapy for Asthma
NCT00377572COMPLETEDPHASE4
419 participants
INTERVENTIONAL
Tucson, United States +7 more
Started: Oct 1, 2006
A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)
NCT01922037COMPLETEDPHASE4
806 participants
INTERVENTIONAL
Birmingham, United States +144 more
Started: Jun 19, 2013
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.
NCT00219323COMPLETEDPHASE3
133 participants
INTERVENTIONAL
Tokyo, Japan
Started: Nov 1, 2003
Study of Omalizumab in Moderate to Severe Bronchial Asthma
NCT00232050COMPLETEDPHASE3
327 participants
INTERVENTIONAL
Started: Oct 1, 2002
Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.
NCT05424523COMPLETED
200 participants
OBSERVATIONAL
East Hanover, United States
Started: Feb 25, 2021
An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma
NCT04607629COMPLETEDPHASE3
192 participants
INTERVENTIONAL
Ufa, Russia +23 more
Started: Jun 20, 2018
Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma
NCT00180011COMPLETEDPHASE2, PHASE3
18 participants
INTERVENTIONAL
New York, United States
Started: Sep 1, 2005
Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.
NCT00500539COMPLETEDPHASE3
155 participants
INTERVENTIONAL
Scottsdale, United States +30 more
Started: Jul 1, 2007
Showing 20 of 112 total trials